Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Cash: 2013-2025

Historic Change in Cash for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -$46.4 million.

  • Ocular Therapeutix's Change in Cash fell 42.78% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 126.05%. This contributed to the annual value of $196.1 million for FY2024, which is 109.77% up from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Change in Cash is -$46.4 million, which was down 211.84% from $41.5 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Change in Cash peaked at $287.1 million during Q1 2024, and registered a low of -$46.4 million during Q3 2025.
  • In the last 3 years, Ocular Therapeutix's Change in Cash had a median value of -$23.3 million in 2023 and averaged $22.0 million.
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 197.20% in 2021, then soared by 1,333.48% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Change in Cash (Quarterly) stood at -$15.1 million in 2021, then fell by 23.37% to -$18.6 million in 2022, then spiked by 557.14% to $85.3 million in 2023, then crashed by 141.19% to -$35.1 million in 2024, then slumped by 42.78% to -$46.4 million in 2025.
  • Its Change in Cash stands at -$46.4 million for Q3 2025, versus $41.5 million for Q2 2025 and -$42.4 million for Q1 2025.